A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury
R Paine III, TJ Standiford, RE Dechert… - Critical care …, 2012 - journals.lww.com
Objectives: To determine whether intravenous infusion of granulocyte-macrophage colony
stimulating factor would improve clinical outcomes for patients with acute lung injury/acute
respiratory distress syndrome. Design: A randomized, double-blind, placebo-controlled
clinical trial of human recombinant granulocyte-macrophage colony stimulating factor vs.
placebo. The primary outcome was days alive and breathing without mechanical ventilatory
support within the first 28 days after randomization. Secondary outcomes included mortality …
stimulating factor would improve clinical outcomes for patients with acute lung injury/acute
respiratory distress syndrome. Design: A randomized, double-blind, placebo-controlled
clinical trial of human recombinant granulocyte-macrophage colony stimulating factor vs.
placebo. The primary outcome was days alive and breathing without mechanical ventilatory
support within the first 28 days after randomization. Secondary outcomes included mortality …